PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary
Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.
How this was made
The 30-second read
Why it matters
Traders can update models using the maintained full-year revenue guidance ($390M–$410M) alongside the lowered U.S. procedure guidance (54,000–56,000) and the stated replacement-cycle expectations through 2027, plus WATER IV enrollment completion and FDA IDE approval for an AF study.
Market read
The key tradable inputs are the guidance split: revenue range held while U.S. procedure outlook was reduced, with the bull case anchored on HYDROS ASP strength and an accelerating replacement cycle.
What to watch
DTC pilots show a 2-4 month lag to procedures, so near-term volume may understate longer-run demand; also, gross margin normalization and tariff recovery could affect earnings quality into 2026.
Background
This is a Q2 2026 earnings call summary for Procept BioRobotics, focused on HYDROS system adoption versus legacy AQUABEAM performance and clinical pipeline progress.
Market effects
Signals continued shift from legacy urology platforms to newer AI-enabled systems, which can influence read-across sentiment for medtech procedure-volume expectations.
U.S.-specific procedure guidance cut may weigh on near-term U.S. medtech procedure-volume sentiment.
Limited direct global read-through beyond the company’s U.S. procedure and replacement-cycle narrative.
Counterpoint
The legacy AQUABEAM softness may be more than temporary disruption; if replacement cycle timing slips, the lowered procedure guidance could dominate despite maintained revenue guidance.
Key entities
- companyProcept BioRobotics Corporation
Guidance update and operational commentary on HYDROS adoption, legacy AQUABEAM softness, and WATER IV clinical progress.
- product_platformHYDROS
New Aquablation system platform highlighted for stronger utilization and record ASPs.
- product_platformAQUABEAM
Legacy platform described as experiencing concentrated softness in certain accounts.
- clinical_trialWATER IV
280-patient trial with primary endpoint results expected in spring 2027.
- clinical_trialWATER IV AF study
FDA IDE approval received to expand the pipeline evaluating Aquablation versus active surveillance.
